A functional role of the glycosylated N-terminal domain of chondromodulin-I. by Kondo, Jun et al.
TitleA functional role of the glycosylated N-terminal domain ofchondromodulin-I.
Author(s)
Kondo, Jun; Shibata, Hiroyuki; Miura, Shigenori; Yamakawa,
Akira; Sato, Koji; Higuchi, Yoshiki; Shukunami, Chisa; Hiraki,
Yuji
CitationJ urnal of bone and mineral metabolism (2011), 29(1): 23-30
Issue Date2011-01
URL http://hdl.handle.net/2433/139525





Jun Kondo, Hiroyuki Shibata, Shigenori Miura, Akira Yamakawa, Koji Sato, Yoshiki 
Higuchi, Chisa Shukunami, and Yuji Hiraki 
 
A functional role of the glycosylated N-terminal domain of chondromodulin-I 
 
J. Kondo 
Advanced Medical Research Laboratory, Research Division, Mitsubishi Tanabe Pharma 
Corporation, Kanagawa 227-0033, Japan. 
 
H. Shibata, S. Miura, K. Sato, C. Shukunami, Y. Hiraki (✉) 
Department of Cellular Differentiation, Institute for Frontier Medical Sciences, Kyoto 
University, Sakyo-ku, Kyoto 606-8507, Japan 
Tel. +81-75-751-4608; Fax +81-75-751-4633 
e-mail: hiraki@frontier.kyoto-u.ac.jp 
 
A. Yamakawa, Y. Higuchi 
Department of Life Science, Graduate School of Life Science, University of Hyogo, 
3-2-1 Koto, Kamigori-cho, Ako-gun, Hyogo 678-1297, Japan 
Tel. +81-791-58-0179; Fax +81-791-58-0177 
 2 
Abstract   Chondromodulin-I (ChM-I) is a 25-kDa glycoprotein that specifically 
localizes in the extracellular matrix of cartilage and negatively regulates angiogenesis. 
ChM-I comprises two domains: an N-terminal hydrophilic domain (Domain 1) 
containing an N-linked glycosylation site and a C-terminal hydrophobic domain 
(Domain 2) with all four disulfide bonds that are present in this protein. We generated a 
non-glycosylated recombinant human ChM-I (NG-hChM-I), and compared its 
bioactivity with that of the glycosylated form of human ChM-I (G-hChM-I) expressed 
in CHO cells in vitro. NG-hChM-I exhibited the growth factor/inhibitor activity in the 
cultures of chondrocytes and vascular endothelial cells, but required markedly higher 
doses. Although Domain 1 is predicted to be hydrophilic per se on the basis of its amino 
acid sequence, NG-hChM-I remains insoluble in aqueous solution as much as 
ΔN-hChM-I that lacks the N-terminal 37 amino acids containing an N-glycosylation site. 
CD (circular dichroism) measurements revealed that the content of α-helix was 
calculated to be 34% in G-hChM-I, whereas the content of the characteristic secondary 
structures in NG-hChM-I was distinctly lower than those in G-hChM-I. These results 
indicate that glycosylation in Domain 1 is critical for the structural integrity for 
biological functions of ChM-I in vitro.  
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Chondromodulin-I (ChM-I) is a cartilage-specific 25-kDa glycoprotein that 
was originally purified as a growth-promoting component of fetal bovine cartilage 
extracts [1, 2], and found to stimulate both DNA synthesis and colony formation in 
cultured chondrocytes in the presence of fibroblast growth factor-2 (FGF2) [1, 3]. 
Thereafter, ChM-I was identified as a cartilage-derived inhibitor of angiogenesis as it 
inhibited DNA synthesis and tube morphogenesis in cultured endothelial cells [4, 5]. 
Gene targetting revealed that the loss of ChM-I gene (Chm1) leads to pathogenic 
angiogenesis and unusual calcification in the cardiac valves [6], which are normally 
maintained in an avascular state and are one of the major sites of Chm1 expression. 
Moreover, the null mice exhibited a phenotype of imbalanced bone remodeling with 
reduced bone turnover [7]. 
The cloning of ChM-I cDNA suggested that the mature human protein (120 
amino acid residues) was encoded as the C-terminal part of a larger type II 
transmembrane precursor (334 amino acid residues) [1]. The human ChM-I gene 
(Chm1) encoding ChM-I maps to 13q14-21, and consists of seven exons and covers a 
genomic region of approximately 40 kb with a TATA-less type promoter [2, 8]. The last 
two exons of this gene encode the mature ChM-I protein. As depicted schematically in 
Fig. 1, exon 6 encodes both the furin processing signal sequence and the N-terminal 
hydrophilic domain (Domain 1), which harbors the conserved N-glycosylation site. 
Moreover, N-terminal amino acid sequencing revealed that naturally occurring bovine 
ChM-I contained two O-oligosaccharide moieties at Thr9 and Thr22 [1], suggesting that 
Domain 1 is heavily glycosylated. However, the functional importance of Domain 1 has 
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been poorly understood. Exon 7 encodes the domain (Domain 2) containing all four 
disulfide bonds and the C-terminal hydrophobic sequence (Fig. 1). The amino acid 
sequences in Domain 2 are conserved among species [9].  
The expression of human ChM-I precursor cDNA in Chinese hamster ovary 
(CHO) cells successfully resulted in the recovery of a mature glycosylated form of this 
protein (G-hChM-I) in the culture media [10]. N-terminal amino acid sequencing of 
G-hChM-I revealed that the expressed ChM-I precursor was properly cleaved at the 
predicted processing signal for the furin endoprotease. However, the produced 
G-hChM-I was recovered as an aggregated form with the apparent molecular size over 
200 kDa due to improper intermolecular disulfide bonds. Therefore, the resultant 
G-hChM-I preparation was then reduced by β-mercaptoethanol or dithiothreitol in the 
presence of 6 M urea, diluted under reoxidation conditions, and purified to homogeneity 
as a monomer form with four intramolecular disulfide bridges [10]. Thus obtained 
recombinant G-hChM-I stimulated the matrix synthesis of cultured chondrocytes and 
inhibited tumor angiogenesis and growth in a xenograft model of human tumor cells in 
vivo [10, 11]. The reduced form of G-hChM-I failed to show any bioactivity on cultured 
chondrocytes and endothelial cells. Reduction of naturally occurring ChM-I loses its 
bioactivity as well [1, 4].  
In our present study, we expressed the mature human ChM-I protein in E. coli, 
and purified the resulting recombinant product in its non-glycosylated form 
(NG-hChM-I) with correctly formed disulfide bridges. Using NG-hChM-I, we 
evaluated the functional significance of each domain within the mature ChM-I protein.  
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Materials and methods 
Materials 
Recombinant G-hChM-I was expressed in CHO cells and purified from the culture 
supernatants as described previously [10]. Escherichia coli BL21 (DE3) cells and the 
pET-11a vector were purchased from Novagen (Madison, WI). Lysozyme and TPCK 
treated trypsin were obtained from Sigma Chemical (St. Louis, MO). V8 protease was 
purchased from Pierce (Rockford, IL).  
Bacterial production and purification of NG-hChM-I 
The sequence encoding the mature form of hChM-I was amplified by PCR from 
pCRII-hChM-I [10] and cloned into NcoI and BamHI sites of pET-11a to generate 
pET11ChM-I. E. coli BL21 (DE3) cells were then transformed with pET11ChM-I and 
NG-hChM-I expression was induced by the addition of 1 mM 
β-D-thiogalactopyranoside. After culturing for a total of 5 h, bacterial cells were 
harvested and the cell pellets (4.4 g in wet weight) were resuspended in 20 ml of lysis 
buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 1 mM EDTA, 0.2 mg/ml 
lysozyme). The insoluble crude debris was suspended in 200 ml of solubilization buffer 
(20 mM Tris-HCl, pH, 9.0, 6 M urea, 1 mM EDTA, and 50 mM DTT) and incubated at 
room temperature overnight with stirring. This solution was then centrifuged at 30,000 
× g for 20 min at 4˚C, and the supernatant was loaded on Q Sepharose FF 
anion-exchange column (2.6 × 32 cm, Amersham Pharmacia Biotech, Buckinghamshire, 
UK) equilibrated with a starting buffer containing 20 mM Tris-HCl, pH 9.0, 6 M urea, 1 
mM EDTA, and 1 mM DTT, and then an SP Sepharose FF cation-exchange column 
(1.6 × 13 cm, Amersham Pharmacia Biotech) equilibrated with a starting buffer 
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comprising 20 mM acetate-NaOH, pH, 5.0, 50 mM NaCl, 6 M urea, 1 mM EDTA, and 
1 mM DTT. The reduced form of the NG-hChM-I protein was eluted with a linear 
gradient of 0-300 mM NaCl and 50-500 mM NaCl, respectively. The eluate was then 
dialyzed against 5% acetic acid and applied to a Butyl-Toyopearl 650 M (1.6 × 13 cm, 
Tosoh, Tokyo, Japan) equilibrated with 0.1% trifluoroacetic acid (TFA). The reduced 
NG-hChM-I was subsequently eluted with a linear gradient from 0 to 80% ethanol and 
the purified protein was worked up by evaporation. A final yield of 59.6 mg of 
NG-hChM-I in the reduced form was recovered from 1200 ml culture of the bacterial 
cells. Protein concentrations were determined by the method of Bradford (Bio-Rad 
Laboratories, Hercules, CA). 
Reoxidation of reduced NG-hChM-I  
An evaporated sample of purified NG-hChM-I in its reduced form was solubilized in 
0.5 ml of buffer containing 10 mM acetate-NaOH, pH 4.7, 6 M urea, and 1 mM EDTA 
to yield a 10 mg/ml protein solution. This solution was diluted into 100 ml of 
reoxidation buffer (50 mM Tris-HCl, pH 9.1, 0.1 M NaCl, 1 mM EDTA, 2 mM 
oxidized glutathione, 0.2 mM reduced glutathione, and 2% CHAPS) to initiate disulfide 
reconstruction. After 4 h incubation at room temperature, acetic acid (5 ml) was added 
to the mixture to stop the reaction. The reoxidized NG-hChM-I was purified using a 
Butyl-Toyopearl 650M (1.6 × 12 cm) and analyzed by reversed phase HPLC as 
described previously [4, 5]. 
Trypsin digestion and peptide mapping of reoxidized NG-hChM-I  
Fifty microliters of a 20 mg/ml preparation of reoxidized NG-hChM-I in 50% ethanol 
was diluted into 950 µl of digestion buffer (0.1 M HEPES-NaOH, pH 6.5 and 2 M urea), 
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and mixed with 36 µg of trypsin. This mixture was then incubated at 37˚C for 12 h with 
gentle mixing, followed by the addition of 50 µl of acetic acid to stop the digestion. The 
fragments were separated by reversed phase HPLC. 
Limited proteolysis of NG-hChM-I with V8 protease  
A 1 ml aliquot of a 10 mg/ml solution of NG-hChM-I in 50% ethanol was added to a 50 
ml volume of reaction buffer (0.1 M ammonium acetate, pH 4.4, and 1 mM EDTA) 
containing 100 µg of V8 protease. After incubation at 37˚C for 30 min, this reaction was 
stopped by the addition of 1 mM phenylmethylsulfonyl fluoride. The digested products 
were then purified and separated by Butyl-Toyopearl 650M (1.6 × 13 cm) and reversed 
phase HPLC. 
Cell culture  
Mouse spleen derived vascular endothelial cell line (MSS31) were a generous gift from 
Dr. Y. Sato (Institute of Development, Aging, and Cancer, Tohoku University) and 
were cultured in alpha-Modified Eagle’s Medium (αMEM) containing 10% fetal bovine 
serum (FBS) at 37˚C under 5% CO2 in air [12]. Human umbilical vein endothelial cells 
(HUVEC) were obtained commercially (Lonza, Walkersville, MD) and cultured in 
endothelial cell growth medium (EGM, Lonza, Walkersville, MD) at 37˚C under 5% 
CO2 in air. Chondrocytes were isolated from rib cartilage of rats by collagenase 
digestion as described previously [13, 14]. 
Bioassays 
DNA synthesis assays were performed using a 5’-bromo-2’-deoxy-uridine (BrdU) 
Labelling and Detection Kit (Roche, Mannheim, Germany). The cells were starved in 
low serum medium and incubated with 2 ng/ml of human fibroblast growth factor-2 and 
 8 
the indicated test molecules. Cells were cultured and labeled with BrdU (25 µl/well) for 
the periods indicated in the figure legends. BrdU incorporation was then assayed using 
an ELISA BrdU chemiluminescence kit according to the manufacturer’s instructions. 
Each experiment was performed three times in quadruplicate. The colony formation 
assay was performed using rat growth plate chondrocytes as previously reported [3, 15]. 
Colony formation was examined on day 8 under a phase-contrast microscope. In vitro 
tube morphogenesis assays were performed in triplicate using Growth factor-reduced 
Matrigel (Becton Dickinson Labware, Bedford, MA) as previously described [16, 17], 
except in the case of HUVECs which were incubated with test samples for 20 min and 
allowed to form tube-like structures for 10 h. 
CD (circular dichroism) measurement 
Far-UV CD measurements were carried out at 10˚C on a J-720WI spectrophotometer 
(JASCO, Tokyo) in the range of 190-270 nm, by using a cell with a light-path of 1 mm. 
G-hChM-I (1 mg/ml) was dissolved in PBS, whereas NG-hChM-I (0.8 mg/ml) was 
dissolved in two different solutions (in 0.1 M sodium acetate buffer, pH 3.8 with 1.4 
mM L-arginine and in 50% ethanol) because of its low solubility in PBS. The solvent 
spectrum obtained under the same conditions was subtracted. CD spectra shown were 
average of five measurements, and the results were expressed as the mean residue 
ellipticity [θ] (deg cm2 dmol-1). 
 9 
Results and discussion 
Non-glycosylated human chondromodulin-I (NG-hChM-I) was expressed in E. coli 
BL21 cells and was produced as inclusion bodies in these bacteria. The expressed 
proteins were therefore extracted using a buffer containing 6 M urea. Without the use of 
a reductant, most of the NG-hChM-I molecules were recovered in a heavily 
polymerized form probably due to intermolecular disulfide bonds. To avoid this, 50 mM 
DTT was included in the extraction buffer. After extraction, NG-hChM-I was purified 
with Q Sepharose, SP Sepharose and Butyl-Toyopearl (Supplemental Fig. 1).  
To convert the reduced NG-hChM-I into its disulfide-bridged form, a 
reoxidation reaction was carried out using oxidized glutathione as a catalyst. The 
reoxidation of NG-hChM-I was monitored using reverse phase HPLC. The reduced 
form of this protein is indicated by a sharp peak at a retention time of 22.9 min (Fig. 
2A). When the proteins were analyzed by HPLC immediately after dilution into the 
reoxidation buffer, no discernible peaks could be observed (0 h in Fig. 2A). Over a short 
incubation time, however, a sharp peak at a retention time of 19.9 min was visible and 
reached a maximum area after 4 h of incubation. Chemical modification analysis further 
indicated that no detectable free sulfhydryl groups were present in this protein 
component (data not shown). The reoxidized product was recovered, and digested with 
trypsin to identify the disulfide bridges. These digested fragments were then separated, 
again using reverse phase HPLC (Fig. 2B). The peaks were subsequently collected and 
identified by N-terminal amino acid sequence analysis. These identified sequences are 
shown in Fig. 2C and no fragments containing either Cys79 or Cys103 were identified. 
Hence, as no free Cys residues were evident in the recovered NG-hChM-I preparation, 
this indicated that these two cysteines had formed a disulfide bond. These disulfide 
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pairings are consistent with those expected from previous structural analysis of naturally 
occurring bovine ChM-I [4, 18].  
We have shown that naturally occurring ChM-I is a bifunctional protein that 
inhibits DNA synthesis in vascular endothelial cells, and that promotes DNA synthesis 
and colony formation of cultured chondrocytes synergistically in the presence of FGF2 
[1, 3, 4]. Purified bovine ChM-I stimulates sulfated proteoglycan synthesis in a 
dose-dependent manner in cultured chondrocytes as well [3, 4]. In either type of cells, 
bioactivity of ChM-I could be discernible at a concentration of several tens ng/ml, 
became evident at 100-300 ng/ml in vitro. At a dose range of 0.5-1 µg/ml, ChM-I gives 
a maximal effect. Recombinant G-hChM-I derived from CHO cells, which was 
prepared by reduction and reoxidation after denaturation in 6 M urea, has shown a 
dose-dependency of bioactivity similar to that of naturally occurring bovine ChM-I [10]. 
In our present study, we examined the effects of NG-hChM-I on DNA synthesis in 
quiescent rat growth plate chondrocytes in culture. As shown in Fig. 3A, NG-hChM-I 
stimulates DNA synthesis in rat primary chondrocytes in the presence of recombinant 
human FGF2 (hFGF2) in a synergistic and dose-dependent manner. The incorporation 
of BrdU into the DNA was found to have increased 4-fold over the basal levels when 
the cells were treated with 30 µg/ml of NG-hChM-I and 2 ng/ml hFGF2. Moreover the 
same dose range of NG-ChM-I (3-10 µg/ml) was found to stimulate the colony 
formation of chondrocytes in agarose cultures in the presence of hFGF2 (1 ng/ml) (Figs. 
3B-E) [3]. However, an approximately 10-fold higher dose of NG-ChM-I is required for 
stimulation of DNA synthesis compared with our previous calculations for naturally 
occurring bovine ChM-I or G-hChM-I [1, 4]. 
Human umbilical vein endothelial cells (HUVECs) spontaneously form 
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capillary-like structures on Matrigel and this reflects in vitro angiogenic processes in 
which cells migrate and join together (Fig. 4A). G-hChM-I derived from CHO cells was 
found to significantly impair the ability of these cells to form capillary-like structures at 
a concentration of 100 ng/ml (Fig. 4B) and 1 µg/ml (Fig. 4C). These data are 
comparable with those of our previous study that used cultured bovine carotid artery 
endothelial cells (Fig. 4G) [10]. In the present study, we further found that NG-hChM-I 
impairs the formation of capillary-like structures in a dose-dependent manner (Figs. 
4D-G). A concentration of 10 µg/ml NG-hChM-I also resulted in a significant inhibition 
of in vitro tube morphogenesis (Figs. 4F and 4G). However, a concentration of 
NG-hChM-I greater than 10 µg/ml did not cause any further inhibition of this process 
(data not shown). These findings indicate that the maximal inhibitory effects of 
NG-hChM-I appear to require a 10-fold higher dose compared with G-hChM-I.  
To study the structural requirements for the functional activity of ChM-I, we 
carried out a limited proteolysis of NG-hChM-I. Incubation of this protein with V8 
protease resulted in its rapid digestion and the accumulation of comparatively larger 
fragments than those generated using other proteases such as trypsin or chymotrypsin 
(Fig. 5A). After about 30 min of digestion, almost all of the NG-hChM-I molecules had 
been fully cleaved and a fragment which migrated slightly faster than the 14-kDa 
marker had accumulated. N-terminal sequencing analysis of this fragment revealed an 
Asp-Ser-Gln-Ala-Phe- sequence, which indicates that the fragment starts from Asp38 in 
the N-terminus of the full length protein (Fig. 1). This digested product (ΔN-hChM-I) 
was then purified by HPLC. To explore the functional significance of the glycosylation 
of ChM-I in Domain 1, a 1 mg aliquot of G-hChM-I or purified NG-hChM-I was 
separately suspended in both PBS and 5% ethanol. After centrifugation, the protein 
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concentrations in the supernatants were measured (Fig. 5B). All three types of 
recombinant ChM-I could be maintained at a 1 mg/ml concentration in 5% ethanol. 
G-hChM-I was found to be soluble in PBS. However, NG-hChM-I was only marginally 
soluble in PBS. It gave only a solution at a concentration of less than 50 µg/ml in PBS. 
ΔN-hChM-I was even less soluble than NG-hChM-I in PBS. Hence, glycosylation in 
Domain 1 enhances the solubility of the ChM-I protein under physiological conditions.  
To assess the bioactivity of ΔN-hChM-I, the mouse spleen-derived vascular 
endothelial cell line, MSS31, was cultured in αMEM containing 10% FBS [12]. These 
cultures were then made quiescent by incubation in low serum medium (αMEM 
containing 0.1% FBS) for 48 h after reaching confluence. As shown in Fig. 6, the 
stimulation of DNA synthesis by hFGF2 (2 ng/ml) was inhibited by G-hChM-I in a 
dose-dependent manner. The concentration of G-hChM-I required for 50% inhibition 
was found to be within the 1-5 µg/ml range. In contrast, the low solubility of 
NG-hChM-I and ΔN-hChM-I hampered the examination of the maximal inhibitory 
doses of these peptides. However, at the near maximal soluble concentration (50 µg/ml) 
of NG-hChM-I or ΔN-hChM-I, the BrdU uptake in MSS31 cells was suppressed by up 
to 75% in comparison with the control cells treated with hFGF2 (2 ng/ml) alone. These 
dose-dependency measurements suggested that an approximately 10-fold or higher dose 
of NG-hChM-I or ΔN-hChM-I than G-hChM-I was required for inhibition of the 
FGF2-induced DNA synthesis (Fig. 6).  
In a similar manner to naturally occurring chondromodulin-I, NG-hChM-I 
was found to be able to exhibit biological activities in chondrocytes and vascular 
endothelial cells, even though this required higher doses when compared with 
glycosylated recombinant protein G-hChM-I (Figs. 3 and 4). This high 
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dose-requirement for NG-hChM-I is likely related to the lower solubility of this 
molecule. Figure 7 compares the CD spectra of G-hChM-I in PBS and NG-hChM-I in 
0.1 M sodium acetate buffer (pH 3.8) with 1.4 mM L-arginine, and in 50% ethanol. The 
negative bands at 208 nm and 222 nm indicate that G-hChM-I in PBS has an α-helical 
structure. The fraction of an α-helix of G-hChM-I is calculated to be 34 % according to 
the equation proposed by Chen and coworkers [19]. In contrast, the CD spectra of 
NG-hChM-I in both solutions do not show distinct characteristic bands for typical 
secondary structures, suggesting that hChM-I molecule does not have a stable 
three-dimensional structure without glycosylation. Even though ΔN-hChM-I that lacks 
most of hydrophilic Domain 1 had an even lower solubility in PBS than the parent 
NG-hChM-I molecule, its growth inhibitory action was indicative in the culture of 
MSS31 cells (Fig. 6). The hydrophobic Domain 2 that contains all four disulfide bonds 
of ChM-I thus appears to be responsible for the biological activities of this protein. This 
is compatible with the fact that reducing agents such as mercaptoethanol or 
dithiothreitol abolished biological activities of G-hChM-I as well as naturally occurring 
bovine ChM-I [4, 10]. We thus conclude that chondromodulin-I contains two structural 
domains, and that each plays a distinct role in transmitting the cellular functions of this 




We thank Dr. Y. Sato (Institute for Development, Aging and Cancer, Tohoku 
University) for providing us with MSS31 endothelial cells. The measurement of CD 
spectra was carried out by using a spectrophotometer installed at Institute for Protein 
Research, Osaka University. We are indebted to Emeritus Prof. Hideo Akutsu at Osaka 
University and Dr. Yuki Takayama at National Institute of Health for their helpful 
discussions for the analysis of CD data. This work was supported in part by the 
Grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology, 




 1. Hiraki Y, Tanaka H, Inoue H, Kondo J, Kamizono A, Suzuki F (1991) Molecular 
cloning of a new class of cartilage-specific matrix, chondromodulin-I, which 
stimulates growth of cultured chondrocytes. Biochem Biophys Res Commun 
175:971-977 
 2. Shukunami C, Oshima Y, Hiraki Y (2005) Chondromodulin-I and tenomodulin: A 
new class of tissue-specific angiogenesis inhibitors found in hypovascular 
connective tissues. Biochem Biophys Res Commun 333:299-307 
 3. Inoue H, Kondo J, Koike T, Shukunami C, Hiraki Y (1997) Identification of an 
autocrine chondrocyte colony-stimulating factor: chondromodulin-I stimulates the 
colony formation of growth plate chondrocytes in agarose culture. Biochem 
Biophys Res Commun 241:395-400 
 4. Hiraki Y, Inoue H, Iyama K, Kamizono A, Ochiai M, Shukunami C, Iijima S, 
Suzuki F, Kondo J (1997) Identification of chondromodulin I as a novel endothelial 
cell growth inhibitor. Purification and its localization in the avascular zone of 
epiphyseal cartilage. J Biol Chem 272:32419-32426 
 5. Hiraki Y, Kono T, Sato M, Shukunami C, Kondo J (1997) Inhibition of DNA 
synthesis and tube morphogenesis of cultured vascular endothelial cells by 
chondromodulin-I. FEBS Lett 415:321-324 
 6. Yoshioka M, Yuasa S, Matsumura K, Kimura K, Shiomi T, Kimura N, Shukunami 
C, Okada Y, Mukai M, Shin H, Yozu R, Sata M, Ogawa S, Hiraki Y, Fukuda K 
(2006) Chondromodulin-I maintains cardiac valvular function by preventing 
angiogenesis. Nat Med 12:1151-1159 
 7. Nakamichi Y, Shukunami C, Yamada T, Aihara K, Kawano H, Sato T, Nishizaki Y, 
 16 
Yamamoto Y, Shindo M, Yoshimura K, Nakamura T, Takahashi N, Kawaguchi H, 
Hiraki Y, Kato S (2003) Chondromodulin I is a bone remodeling factor. Mol Cell 
Biol 23:636-644 
 8. Yanagihara I, Yamagata M, Sakai N, Shukunami C, Kurahashi H, Yamazaki M, 
Michigami T, Hiraki Y, Ozono K (2000) Genomic organization of the human 
chondromodulin-1 gene containing a promoter region that confers the expression of 
reporter gene in chondrogenic ATDC5 cells. J Bone Miner Res 15:421-429 
 9. Sachdev SW, Dietz UH, Oshima Y, Lang MR, Knapik EW, Hiraki Y, Shukunami 
C (2001) Sequence analysis of zebrafish chondromodulin-1 and expression profile 
in the notochord and chondrogenic regions during cartilage morphogenesis. Mech 
Dev 105:157-162 
10. Hiraki Y, Mitsui K, Endo N, Takahashi K, Hayami T, Inoue H, Shukunami C, 
Tokunaga K, Kono T, Yamada M, Takahashi HE, Kondo J (1999) Molecular 
cloning of human chondromodulin-I, a cartilage-derived growth modulating factor, 
and its expression in Chinese hamster ovary cells. Eur J Biochem 260:869-878 
11. Hayami T, Shukunami C, Mitsui K, Endo N, Tokunaga K, Kondo J, Takahashi HE, 
Hiraki Y (1999) Specific loss of chondromodulin-I gene expression in 
chondrosarcoma and the suppression of tumor angiogenesis and growth by its 
recombinant protein in vivo. FEBS Lett 458:436-440 
12. Yanai N, Satoh T, Obinata M (1991) Endothelial cells create a hematopoietic 
inductive microenvironment preferential to erythropoiesis in the mouse spleen. Cell 
Struct Funct 16:87-93 
13. Shimomura Y, Suzuki F (1984) Cultured growth cartilage cells. Clin Orthop Relat 
Res 93-105 
 17 
14. Shukunami C, Iyama K, Inoue H, Hiraki Y (1999) Spatiotemporal pattern of the 
mouse chondromodulin-I gene expression and its regulatory role in vascular 
invasion into cartilage during endochondral bone formation. Int J Dev Biol 
43:39-49 
15. Kato Y, Iwamoto M, Koike T (1987) Fibroblast growth factor stimulates colony 
formation of differentiated chondrocytes in soft agar. J Cell Physiol 133:491-498 
16. Oshima Y, Shukunami C, Honda J, Nishida K, Tashiro F, Miyazaki J, Hiraki Y, 
Tano Y (2003) Expression and localization of tenomodulin, a transmembrane type 
chondromodulin-I-related angiogenesis inhibitor, in mouse eyes. Invest Ophthalmol 
Vis Sci 44:1814-1823 
17. Oshima Y, Sato K, Tashiro F, Miyazaki J, Nishida K, Hiraki Y, Tano Y, 
Shukunami C (2004) Anti-angiogenic action of the C-terminal domain of 
tenomodulin that shares homology with chondromodulin-I. J Cell Sci 
117:2731-2744 
18. Neame PJ, Treep JT, Young CN (1990) An 18-kDa glycoprotein from bovine nasal 
cartilage. Isolation and primary structure of small, cartilage-derived glycoprotein. J 
Biol Chem 265:9628-9633. 
19. Chen YH, Yang JT, Martinez HM (1972) Determination of the secondary structures 




Figure Legends  
FIG. 1.  The structure of human Chondromodulin-I.  Amino acid sequence of the 
human ChM-I protein and configuration of its disulfide bonds are shown. The disulfide 
bond arrangements are assumed to be identical with those of ChM-I purified from 
bovine fetal cartilage [1, 4, 14, 18]. The residues indicated in green circles indicate the 
amino acids that are not conserved in the mouse ChM-I protein [14].  
 
FIG. 2.  Reverse-phase chromatographic analysis of NG-hChM-I during 
reoxidation.  (A) The catalyzed reoxidation of NG-hChM-I was carried out using 
glutathione as described in “Materials and methods.” After this reaction was stopped by 
the addition of acetic acid, 10 µg of protein was injected into a YMC-Pack C4-AP 
HPLC column. Elution of the proteins (at a flow rate of 1 ml/min) was monitored by the 
measurement of absorbance at 210 nm. The retention times between 17 min and 25 min 
are shown in the figure. The reduced and oxidized forms of NG-hChM-I were eluted at 
23 and 20 min, respectively. (B) A reverse phase chromatogram of tryptic fragments of 
NG-hChM-I is shown. The numbered peaks correspond to fragments containing 
disulfide bridges. The peaks labeled with an asterisk have the same N-terminal sequence, 
LNNETRPSVQED. (C) N-terminal sequencing of the numbered fragments shown in 
(B). Fragment #1 was found to contain the same N-terminal sequence as fragment #2 
except for digestion at Tyr94-Asn95. 
 
FIG. 3.  Stimulation of DNA synthesis and colony formation in rat chondrocytes by 
NG-hChM-I in the presence of hFGF2.  (A) Quiescent rat primary chondrocytes in 
48-multiwell culture plates were stimulated by 2 ng/ml of hFGF2 with or without the 
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indicated concentration of recombinant NG-hChM-I for 22 h. Thereafter BrdU was 
added to the cultures followed by incubation for another 4 h. Incorporation of BrdU into 
the cells was determined using an ELISA BrdU chemiluminescence kit according to the 
manufacturer’s instructions. This experiment was repeated three times with similar 
results. (B-E) Rat primary chondrocytes (5 × 103 cells/well) were suspended in 0.41% 
agarose in F-12 medium containing 5% FBS, 2 × 10-7 M hydrocortisone, and 60 µg/ml 
transferrin. The cell suspensions were then overlaid on a base agarose layer. After 
incubation overnight, the indicated factors were added to the cells. On day 8, colony 
formation was examined under a phase-contrast microscope. Cells were treated with 
0.1% BSA alone (B), 1 ng/ml hFGF2 (C), 3 µg/ml NG-hChM-I in the presence of 1 
ng/ml hFGF2 (D), and 10 µg/ml NG-hChM-I in the presence of 1 ng/ml hFGF2 (E). Bar, 
100 µm. 
 
FIG. 4.  Inhibition of tube morphogenesis in vitro by recombinant human 
ChM-I.  (A-F) Quiescent HUVECs were plated on growth factor-reduced Matrigel with 
αMEM containing 0.5% FBS with or without test samples. (A) HUVECs were plated on 
Matrigel without ChM-I. (B, C) Cells were cultured in the presence of G-hChM-I (panel 
B, 0.1 µg/ml; panel C, 1.0 µg/ml). (D-F) Cells were cultured in the presence of 
NG-ChM-I (panel D, 0.1 µg/ml; panel E, 1.0 µg/ml; panel F, 10 µg/ml). All 
photographs are representative of four standardized fields from three separate 
experiments. Bar, 200 µm. (G) Tube morphogenesis of HUVECs was quantitatively 
evaluated by measuring the total lengths of the tube-like structures in randomly selected 
fields with NIH image version 1.61. Four standardized-fields in each experiment were 
randomly chosen for measurement. Each value is the mean ± S.D. of data from three 
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separate experiments.  
 
FIG. 5.  Generation and solubility of the purified N-terminal truncated fragment of 
ChM-I (ΔN-hChM-I).  (A) Limited proteolysis of NG-hChM-I by V8 protease.  The 
reaction conditions are described in “Materials and methods.” At a given time period, an 
aliquot of the reaction mixture was withdrawn and added to SDS-PAGE sample buffer 
to stop the reaction. Then samples were then resolved in a 15% polyacrylamide gel and 
the proteins were stained with Coomassie Brilliant Blue R250. Samples were taken at 0 
min (lane 1), 5 min (lane 2), 10 min (lane 3), 15 min (lane 4), 20 min (lane 5), 25 min 
(lane 6), 30 min (lane 7), 40 min (lane 8), 50 min (lane 9), and 60 min (lane 10). In lane 
11, the N-terminal truncated fragment that was purified by preparative HPLC was 
loaded. Molecular weight markers are shown in lane 12. (B) One milligram each of 
NG-hChM-I, ΔN-hChM-I, and G-hChM-I was dissolved in 1 ml of PBS (closed bars) or 
5% ethanol (open bars), and after centrifugation the protein concentrations of the 
supernatant were measured using the Bradford assay. All of the derivatives were 
completely soluble in 5% ethanol. The solubilities of these products in PBS are shown 
relative to in those in 5% ethanol. 
 
FIG. 6.  Inhibition of DNA synthesis of MSS31 cells by recombinant human ChM-I 
and its derivatives.  Quiescent MSS31 cells in 48-multiwell culture plates were 
stimulated with a 2 ng/ml dose of hFGF2 and then cultured with the indicated 
concentrations of recombinant human ChM-I for 24 h. Thereafter, BrdU was added to 
the cultures, which were incubated for a further 12 h. The incorporation of BrdU into 
the cells was subsequently determined using ELISA BrdU chemiluminescence. These 
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experiments were repeated three times and gave similar results.  
 
FIG. 7.  Far-UV CD spectra of G-hChM-I and NG-hChM-I.  CD spectra of G-hChM-I 
in PBS (black solid line), and of NG-hChM-I in 0.1 M sodium acetate buffer pH 3.8 
with 1.4 mM L-arginine (gray solid line) and in 50 % ethanol (black dotted line) are 
shown. 
 
Legends for Supplemental Data 
Supplemental Fig. 1.  SDS-PAGE analysis (15%) of NG-hChM-I under reduced 
conditions during purification. Proteins were stained with Coomassie Brilliant Blue 
R250. Lane 1, total cells; lane 2, extracts with urea and DTT; lane 3, Q Sepharose 
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